Physician profile
Kezia A Daniel
NPI 1508245721
$786.30
in general payments reported to CMS, 2019-2025
18 companies · $27.20 in 2025
The $27.20 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $166 · 2021: $169 · 2022: $17.21 · 2023: $41.78 · 2024: $175 · 2025: $27.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $124.79 | 2024 | |
| Ucb, INC. | $95.65 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $82.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.13 | 2020-2021 | |
| Eisai INC. | $62.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $48.82 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $45.12 | 2019-2021 | |
| Abbvie INC. | $40.79 | 2020 | |
| Genentech USA, INC. | $29.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.05 | 2019-2020 | |
| Astellas Pharma US INC | $22.25 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.86 | 2019 | |
| Electromed, INC. | $21.12 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.16 | 2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $18.47 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $17.84 | 2020 | |
| Glaxosmithkline, LLC. | $17.21 | 2022 | |
| Allergan, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kezia Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.